Microblepharoexfoliation (MBE) is an effective, noninvasive adjunctive treatment method for chalazion resolution, according to a study published in Cornea.
Researchers enrolled 50 participants with acute chalazia in a prospective, randomized clinical trial and randomly assigned them to treatment with MBE and lid hygiene (n=23; mean age, 66.6±6.6 years) or lid hygiene alone (n=27; mean age, 62.1±14.4 years). Chalazion resolution was evaluated at a 1-month follow-up visit.
One eyelash was epilated from each participant and examined for Demodex. The number of Demodex mites on the lash was recorded during the initial and follow-up visits.
Participants underwent comprehensive examinations, tear osmolarity testing, lissamine green staining of the ocular surface, matrix metalloproteinase-9 (MMP-9) tear level testing, and Schirmer 1 analysis during the 1-month follow-up visit and completed the ocular surface disease index (OSDI) to assess dry eye symptomatology.
Investigators report that participants treated with both lid hygiene and MBE demonstrated a statistically significant chalazion resolution compared with those treated with lid hygiene alone (P =.007).
A total of 87% of individuals treated with MBE and lid hygiene experienced chalazion resolution compared with 44% of participants who used lid hygiene alone. Overall, 22% of patients with chalazia were positive for Demodex in their lashes.
“MBE, a completely noninvasive treatment modality, achieved resolution rates comparable or even slightly higher than those of the historically more invasive injections and [incision and curettage] procedures” according to the researchers. They also report, “the efficacy of MBE is less likely to be related to the presence of Demodex in the patients’ lashes.”
Study limitations include a short follow-up duration, small sample size, and use of a single center.
Zhu D, Gupta RR, Stein RL, et al. Randomized prospective evaluation of microblepharoexfoliation BlephEx as adjunctive therapy in the treatment of chalazia. Cornea. Published online July 7, 2022. doi:10.1097/ICO.0000000000003090